Status:
COMPLETED
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Lead Sponsor:
HIV Vaccine Trials Network
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
An observational study of long-term outcomes of HIV-1 infection in persons who become infected after enrollment in HIV-1 vaccine trials
Detailed Description
A descriptive and observational study of long-term outcomes of HIV-1 infection in persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
Eligibility Criteria
Inclusion
- Participants must meet the following criteria in order to be eligible for inclusion in the study:
- Confirmation of HIV-1 infection after enrollment in an HVTN vaccine trial in which HIV-1 infection constituted an endpoint, according to the diagnostic algorithm specified in the parent protocol.
- Ability and willingness to provide written informed consent to participate in the study.
- Ability and willingness to adhere to the on-study follow-up schedule.
- Ability and willingness to provide adequate information for locator purposes.
- Participants who are currently on ART or who previously received antiretrovirals as part of post-exposure prophylaxis, pre-exposure prophylaxis, or previous treatment regimen will be eligible for inclusion in this protocol. Their previous treatment history will be collected. If a participant has been on ART for more than 2 years, please consult with the protocol team leadership prior to enrollment.
- For participants initiating ART, agreement of participant and PHCP to initiate potent and durable ART regimens in accordance with local and international guidelines. Examples of potent and durable regimens are provided in Appendix H. Participants who initiate ART not consistent with regimens outlined in Appendix H may enroll with permission of the protocol chair or designee(s).
Exclusion
- Persons who meet the following criteria will be excluded from the study:
- Any medical, psychiatric, alcohol/drug dependency or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a participant's ability to give informed consent.
- Participants who meet these additional criteria will be excluded from the study:
- Participants undergoing acute therapy for serious medical illnesses (in the opinion of the site investigator) within 14 days prior to initiation of ART.
- Participants with chronic, acute, or recurrent infections that are serious (in the opinion of the site investigator).
- Participants who must continue with chronic (maintenance) therapy (e.g., tuberculosis \[TB\], pneumocystis pneumonia \[PCP\]), must have completed at least 14 days of therapy and be clinically stable prior to initiation of ART.
- Oral and vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses, as defined by the site investigator, present no restriction to eligibility.
- Participants undergoing radiation therapy, systemic chemotherapy, or receiving an immunomodulator within 45 days prior to initiation of ART. (A tapering course of corticosteroids as acute therapy for PCP or other conditions is an exception.)
Key Trial Info
Start Date :
July 11 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT03337906
Start Date
July 11 2008
End Date
July 1 2016
Last Update
April 18 2022
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Vaccine CRS
Birmingham, Alabama, United States, 35294
2
Bridge HIV CRS
San Francisco, California, United States, 94143
3
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, United States, 30030
4
UIC Project WISH CRS
Chicago, Illinois, United States, 60612